The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1NUHM4     ethyl2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4...

Synonyms: CHEMBL522038, CHEBI:65172, Exanta (proposed), 140428-EP2277565A2, 140428-EP2277566A2, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Exanta


Psychiatry related information on Exanta


High impact information on Exanta


Chemical compound and disease context of Exanta


Biological context of Exanta


Anatomical context of Exanta


Associations of Exanta with other chemical compounds


Gene context of Exanta


Analytical, diagnostic and therapeutic context of Exanta


  1. New anticoagulants. Hirsh, J., O'Donnell, M., Weitz, J.I. Blood (2005) [Pubmed]
  2. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. Sarich, T.C., Wolzt, M., Eriksson, U.G., Mattsson, C., Schmidt, A., Elg, S., Andersson, M., Wollbratt, M., Fager, G., Gustafsson, D. J. Am. Coll. Cardiol. (2003) [Pubmed]
  3. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Heit, J.A., Colwell, C.W., Francis, C.W., Ginsberg, J.S., Berkowitz, S.D., Whipple, J., Peters, G. Arch. Intern. Med. (2001) [Pubmed]
  4. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. Petersen, P., Grind, M., Adler, J. J. Am. Coll. Cardiol. (2003) [Pubmed]
  5. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Douketis, J.D., Arneklev, K., Goldhaber, S.Z., Spandorfer, J., Halperin, F., Horrow, J. Arch. Intern. Med. (2006) [Pubmed]
  6. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Olsson, S.B. Lancet (2003) [Pubmed]
  7. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. Halperin, J.L. J. Am. Coll. Cardiol. (2005) [Pubmed]
  8. Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Cullberg, M., Eriksson, U.G., Wåhlander, K., Eriksson, H., Schulman, S., Karlsson, M.O. Clin. Pharmacol. Ther. (2005) [Pubmed]
  9. Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. Wåhlander, K., Eriksson-Lepkowska, M., Nyström, P., Eriksson, U.G., Sarich, T.C., Badimon, J.J., Kalies, I., Elg, M., Bylock, A. Thromb. Haemost. (2006) [Pubmed]
  10. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Wallentin, L., Wilcox, R.G., Weaver, W.D., Emanuelsson, H., Goodvin, A., Nyström, P., Bylock, A. Lancet (2003) [Pubmed]
  11. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Wåhlander, K., Eriksson-Lepkowska, M., Frison, L., Fager, G., Eriksson, U.G. Clinical pharmacokinetics. (2003) [Pubmed]
  12. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Eriksson, U.G., Mandema, J.W., Karlsson, M.O., Frison, L., Gisleskog, P.O., Wählby, U., Hamrén, B., Gustafsson, D., Eriksson, B.I. Clinical pharmacokinetics. (2003) [Pubmed]
  13. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Johansson, L.C., Andersson, M., Fager, G., Gustafsson, D., Eriksson, U.G. Clinical pharmacokinetics. (2003) [Pubmed]
  14. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Johansson, L.C., Frison, L., Logren, U., Fager, G., Gustafsson, D., Eriksson, U.G. Clinical pharmacokinetics. (2003) [Pubmed]
  15. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Eriksson, U.G., Bredberg, U., Hoffmann, K.J., Thuresson, A., Gabrielsson, M., Ericsson, H., Ahnoff, M., Gislén, K., Fager, G., Gustafsson, D. Drug Metab. Dispos. (2003) [Pubmed]
  16. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Clement, B., Lopian, K. Drug Metab. Dispos. (2003) [Pubmed]
  17. Medical indications and considerations for future clinical decision making. Haas, S. Thromb. Res. (2003) [Pubmed]
  18. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Gustafsson, D., Nyström, J., Carlsson, S., Bredberg, U., Eriksson, U., Gyzander, E., Elg, M., Antonsson, T., Hoffmann, K., Ungell, A., Sörensen, H., Någård, S., Abrahamsson, A., Bylund, R. Thromb. Res. (2001) [Pubmed]
  19. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Eriksson, U.G., Johansson, S., Attman, P.O., Mulec, H., Frison, L., Fager, G., Samuelsson, O. Clinical pharmacokinetics. (2003) [Pubmed]
  20. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Bredberg, E., Andersson, T.B., Frison, L., Thuresson, A., Johansson, S., Eriksson-Lepkowska, M., Larsson, M., Eriksson, U.G. Clinical pharmacokinetics. (2003) [Pubmed]
  21. No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. Sarich, T.C., Schützer, K.M., Wollbratt, M., Wall, U., Kessler, E., Eriksson, U.G. Journal of clinical pharmacology. (2004) [Pubmed]
  22. Current anticoagulant therapy--unmet clinical needs. Hirsh, J. Thromb. Res. (2003) [Pubmed]
  23. The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol. Sarich, T.C., Johansson, S., Schützer, K.M., Wall, U., Kessler, E., Teng, R., Eriksson, U.G. Journal of clinical pharmacology. (2004) [Pubmed]
  24. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Gomberg-Maitland, M., Wenger, N.K., Feyzi, J., Lengyel, M., Volgman, A.S., Petersen, P., Frison, L., Halperin, J.L. Eur. Heart J. (2006) [Pubmed]
  25. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Eriksson, B.I., Agnelli, G., Cohen, A.T., Dahl, O.E., Mouret, P., Rosencher, N., Eskilson, C., Nylander, I., Frison, L., Ogren, M. Thromb. Haemost. (2003) [Pubmed]
  26. Clinical experience with ximelagatran in orthopaedic surgery. Eriksson, B. Drugs (2004) [Pubmed]
WikiGenes - Universities